CNMD Q3 deep dive: stable revenue, margin improvement, and focus on core growth platforms

Medical tech company CONMED (NYSE:CNMD) met Wall Street’s revenue expectations in Q3 2026, but sales were flat year on year at $335.6 million. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $1.36 billion at the midpoint. Its non-GAAP profit of $1.04 per share was 3.7% above analysts’ consensus estimates.

Is now the time to buy CNMD? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

CONMED’s third quarter reflected stability in its core business, with year-over-year sales holding flat and revenue meeting Wall Street’s expectations. Management attributed the quarter’s results to solid execution in both general and orthopedic surgery product lines, highlighting strong international growth and contributions from flagship products such as AirSeal, Buffalo Filter, and BioBrace. CEO Patrick J. Beyer noted, “Our AirSeal sales growth was driven primarily by stable growth in sales of disposables and strong growth in capital equipment, particularly outside the US.” While domestic orthopedic performance remained soft due to ongoing commercial reorganization, international momentum helped offset these challenges.

Looking ahead, CONMED’s full-year guidance remains closely aligned with analyst expectations, with management emphasizing the importance of continued commercial execution and targeted investments in high-potential markets. CFO John E. Gallagher stated, “We remain confident in our team's ability to deliver at least 5% organic constant currency growth in 2026,” while also noting that efforts to expand AirSeal adoption and drive Buffalo Filter’s direct business are expected to underpin growth. The company’s refined focus on minimally invasive surgery, smoke evacuation, and orthopedic soft tissue repair is central to its strategy for sustaining profitability and navigating a competitive landscape.

Key insights from management’s remarks

Management identified targeted product execution and commercial optimization as key drivers of the quarter’s performance, alongside the impact of portfolio rationalization and legislative tailwinds in smoke evacuation.

• International growth momentum: Strong sales outside the U.S.—especially in EMEA (Europe, Middle East, and Africa) and APAC (Asia-Pacific)—drove broad-based gains across both general and orthopedic surgery product lines, helping offset weaker domestic trends.
• AirSeal expansion and differentiation: The AirSeal insufflation platform benefited from a newly expanded U.S. clinical indication for use with Intuitive’s da Vinci 5 system, as well as growing adoption in robotic procedures. Management highlighted AirSeal’s clinical advantages, such as reduced procedure time and improved patient outcomes, as key to its increasing market share.
• Buffalo Filter direct portfolio supported by regulation: Direct sales of Buffalo Filter’s surgical smoke evacuation products delivered growth in the high single to low double-digit range, supported by new state-level laws mandating smoke evacuation. Management cited 23 states now requiring smoke-free operating rooms, covering about 60% of the U.S. population, as an ongoing tailwind. However, sales to OEM customers declined, which tempered overall Buffalo Filter performance.
• Orthopedic sales mixed by region: International orthopedic sales rose strongly, while U.S. orthopedic sales saw a 1.7% year-on-year decline due to ongoing changes in the commercial organization. Management expressed confidence that these changes will position the domestic business for more stable growth ahead.
• Portfolio optimization and focus: The exit from GI (gastroenterology) products allowed CONMED to concentrate resources on core growth areas—minimally invasive surgery, smoke evacuation, and orthopedic soft tissue repair—improving focus.

Drivers of future performance

Management expects future growth to be driven by targeted product expansion, commercial execution, and regulatory trends supporting adoption in core markets.

• AirSeal and Buffalo Filter direct growth: Management is prioritizing increased adoption of AirSeal in both robotic and laparoscopic surgery, particularly in underpenetrated U.S. segments. Legislative mandates for smoke evacuation are expected to drive further demand for Buffalo Filter’s direct sales portfolio, which management believes will support strong, durable growth.
• Orthopedic recovery and global expansion: The ongoing restructuring of the U.S. orthopedic salesforce is expected to return domestic growth to positive territory in the coming quarters. International expansion of products like BioBrace, with recent regulatory wins in markets such as Brazil, is seen as a long-term growth lever.
• Operational and margin focus: Management flagged gross margin as an area of scrutiny, noting that international mix and discrete operational items modestly pressured margins this quarter. The company is targeting improved free cash flow and continued deleveraging, while remaining open to accretive M&A opportunities as balance sheet capacity improves.

Catalysts in upcoming quarters

In the coming quarters, the StockStory team will watch for (1) progress in AirSeal adoption and penetration in U.S. laparoscopic procedures, (2) continued legislative momentum for smoke evacuation, which could accelerate Buffalo Filter’s growth, and (3) evidence that domestic orthopedic sales are rebounding as commercial changes take hold. The pace of international expansion and margin stabilization will also be important markers of execution.

CONMED currently trades at $45.57, in line with $45.76 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free).

Now could be the perfect time to invest in these stocks

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.